LB Pharmaceuticals Appoints Joseph Miller CFO
LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple
Stocks · News reference
HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates LB Pharmaceuticals (NASDAQ:LBRX) with a Buy and maintains $45 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — LB PHARMACEUTICALS INC (LBRX)
Filed: 2026-09-03 AccNo: 0001193125-26-381076 Size: 174 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts change outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page. Follow other analysts.
HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60